Share

June 2023; 9 (3) Research ArticleOpen Access

Machine Learning Approach for the Prediction of Age-Specific Probability of SCA3 and DRPLA by Survival Curve Analysis

Yuya Hatano, Tomohiko Ishihara, Sachiko Hirokawa, Osamu Onodera
First published May 4, 2023, DOI: https://doi.org/10.1212/NXG.0000000000200075
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
194

Share

Article Information

vol. 9 no. 3 e200075
DOI: 
https://doi.org/10.1212/NXG.0000000000200075
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received October 6, 2022
  • Accepted in final form March 23, 2023
  • First Published May 4, 2023.
Copyright & Usage: 
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Yuya Hatano, MD, PhD,
    2. Tomohiko Ishihara, MD, PhD,
    3. Sachiko Hirokawa, MS and
    4. Osamu Onodera, MD, PhD
  1. Yuya Hatano, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. <br>a Grant-in-Aid from Tsubaki Memorial Foundation<br>a Grant-in-Aid from Kyowakai Igaku Kenkyu Joseikin<br>

    Research Support, Foundations and Societies:

    1. <br>a Grant-in-Aid from SERIKA Foundation<br> Signature: Yuya Hatano Date: 2023/03/23<br><br>

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Tomohiko Ishihara, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. <br>(1)Japan Society for the Promotion of Science, Grant-in-aid <br>for Scientific Research , 21K07272, 2021<br> Signature: Tomohiko Ishihara Date: 2023/3/23<br><br>

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sachiko Hirokawa, MS and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Osamu Onodera, MD, PhD
    5. Scientific Advisory Boards:

    1. <br>Scientific advisory board: Kissei Pharm.<br>

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. <br>Speaker honoraria: Kyowa Hakko Kirin Co., Ltd., Bristol-Myers <br>Squibb, Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharm, <br>Takeda, Daiichi-Sankyo, FUJIFILM, SANOFI, FP-pharm.<br>

    Editorial Boards:

    1. <br>Associate editor of International Journal of Neurochemistry.<br>

    Patents:

    1. <br>Association of htra1 mutations and familial ischemic cerebral <br>small-vessel disease <br>US 20120100536 A1<br>

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. <br>Supported in part by a Grant-in-Aid for Scientific<br>Research on Priority Areas “Advanced Brain Science<br>Project” and “Applied Genomics”; a grant from the Research<br>Committee for Hereditary Cerebral Small Vessel Diseases,<br>Research on Measures for Intractable Diseases, from the<br>Ministry of Health, Labor, and Welfare of Japan<br> Signature: Osamu Onodera Date: 2023/03/23

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology, Brain Research Institute, Niigata University, Niigata-shi, Japan.
  1. Correspondence
    Dr. Ishihara ishihara{at}bri.niigata-u.ac.jp
View Full Text

Article usage

Article usage: May 2023 to August 2023

AbstractFullPdfSource
May 20231161798Highwire
Jun 2023523950Highwire
Jul 20231015128Highwire
Aug 202378618Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me